The Oncology Institute Refinances $86M Debt with OrbiMed, Extending Maturity to 2031
Event summary
- The Oncology Institute repaid $86M in senior secured convertible notes to Deerfield Partners through a refinancing deal with OrbiMed.
- New financing includes a $75M term loan from OrbiMed maturing in 2031 and $11M in cash from the balance sheet, avoiding additional equity dilution.
- Transaction aims to increase liquidity, improve operating flexibility, and extend debt maturities.
The big picture
The Oncology Institute’s refinancing with OrbiMed underscores the growing reliance on specialized healthcare financiers to support value-based oncology models. The move aligns with broader industry trends of consolidating debt and extending maturities amid regulatory and reimbursement uncertainties. With over 100 clinics across five states, TOI’s financial maneuvering could set a precedent for mid-sized provider groups balancing growth with balance sheet discipline.
What we're watching
- Debt Management
- How the extended maturity timeline will impact TOI’s financial flexibility and ability to pursue growth initiatives.
- Operational Flexibility
- Whether the improved liquidity positions TOI to navigate reimbursement pressures or competitive challenges more effectively.
- Strategic Partnerships
- The role OrbiMed may play in future financing rounds or strategic decisions as a key creditor.